(Adnkronos) - “Ci sono molte novità nel campo dell'emicrania dal 2019 ad oggi: sono arrivate sul nostro mercato sette molecole nuove, di cui una per il trattamento sintomatico, mentre gli altri farmaci sono tutti per il trattamento preventivo. Il trattamento preventivo è importantissimo in quanto serve a ridurre la frequenza degli attacchi”. Lo ha detto Cristina Tassorelli, professoressa di Neurologia università di Pavia, in occasione del 54° Congresso Sin - Società italiana di neurologia, in svolgimento a Roma fino al 12 novembre.
Category
🗞
NewsTranscript
00:00There are many novelties in the field of hemicrania, from 2019 to today, so we are talking about 5 years, 7 new molecules have arrived on our market.
00:157 new molecules, one for the symptomatic treatment, so the attack starts and I have to make it go away, and the other drugs are all for the preventive treatment.
00:26Preventive treatment is very important because it is used to reduce the frequency of attacks, not to make them really come, or those that are suspected to have a lower intensity.
00:37In this case we have 4 monoclonal antibodies, the first one came out in 2019 and then 3 more followed, of which 3 are supplied for subcutaneous pathology and 1 is supplied for endovenous pathology.
00:50They have revolutionized the scenario because the hemicranian was used to treat his disease with pills if needed, pills to prevent, often more pills during the day, non-specific drugs, sometimes aggravated by major side effects.
01:08In this case, monoclonal drugs are drugs that can be supplied, some for subcutaneous pathology, others for endovenous pathology, once a month, once every 3 months, it depends, there are some differences between them, however, let's say that one injection is for 1 month, for 3 months the person is covered.
01:27Then, in the novelty, other 2 drugs came out, which are also specific for the hemicrania, when I say specific I mean that they block one of the mediators of the hemicrania that has a very important role in the attacks.
01:41This mediator is a small neuropeptide, but very aggressive, which has a rather long name, which is calcitonin gene-related peptide, and therefore also these 2 new ones that I was saying are more recent, they attack, block this peptide, so they block its biological effects, the difference is that they are supplied for oral life.
02:07It would seem a step back, but it is not, in fact, it is to give more options to people, to patients, because if monoclonal drugs have a duration in the body of 28 days and more, these have a duration of 11 hours, which can have its advantages, both as a speed of action and also as a speed of washing of the body in case it should interrupt.
02:31There are 2 effective drugs that are available, for one we have the reimbursability recently, it is the togepant, which is available in the 60 mg dosage once a day, with data of effectiveness and absolutely convincing tolerability, and the other, which is called remagepant, AIFA has not yet defined the path of reimbursability, also he, gepanto, for oral life, novelty in novelty, is a drug,
03:01which has shown effectiveness, both in the symptomatic treatment, so taken when needed, and in the prevention treatment, so taken, in this case, once in a while.